Analyst Ratings For Galmed Pharmaceuticals (NASDAQ:GLMD)
Today, Galmed Pharmaceuticals (NASDAQ:GLMD) stock received an upgrade by Maxim Group from Hold to Buy with a price target of $14.00.
Some recent analyst ratings include
- 3/15/2018-Maxim Group Upgrade from a “Hold ” rating to a ” Buy” rating.
- 11/15/2017-Roth Capital initiated coverage with a Buy rating.
- 10/6/2017-Seaport Global Securities Reiterated Rating of Buy.
Recent Trading Activity for Galmed Pharmaceuticals (NASDAQ:GLMD)
Shares of Galmed Pharmaceuticals closed the previous trading session at with 6.909999847412109 shares trading hands.